It hasn't been a great 2021 so far for the CSL (ASX:CSL) share price

What's been impacting the biotech giant's shares this years?

The CSL Limited (ASX: CSL) share price has remained relatively flat when compared to the beginning of the year, up less than 3%. In comparison, the S&P/ASX 200 Index (ASX: XJO) is up almost 14% year to date.

During Wednesday's trading session, CSL shares continued to move largely sideways, sliding 0.69% to $292.28.

a doctor with stethoscope around neck sits as a computer with head in hand, looking despondent.

Image source: Getty Images

How is CSL comparing against the ASX 200?

On average, the ASX 200 has returned 6.50% per annum to shareholders over the last 5 years, and 5.78% per annum over its 10-year chart. The most significant gain was achieved in 2019 when the index grew 23.02%. On the other hand, the biggest fall came in 2011, when it lost 10.84%. Surprisingly, despite the pandemic-induced crash in 2020, that year did not deliver the biggest losses thanks to the ASX 200's sharp rebound.

Why is it worth looking at the 5-year and 10-year gains of the ASX 200? The reason is that, historically, CSL shares have outperformed the ASX 200 by a significant margin. Over the past 5 years, the company has delivered a 155% return. When looking at the last 10 years, the CSL share price has jumped by around 930% over the period.

What's been affecting the CSL share price lately?

CSL has been marred with plasma collection issues stemming from early 2020 when COVID-19 arrived on the world stage. Governments around the world enforced restrictions on passenger movements and closed down international borders in an effort to help curb the spiralling outbreak.

This was particularly bad news for CSL as it relies on the plasma from blood donors to make its life-saving medicines.

The company last provided an update in March advising that December 2020 plasma volumes were sitting at around 80% of December 2019 levels.

While current plasma levels are expected to eventually bounce back, no one can be certain exactly when this will occur. This uncertain environment has likely weighed on investor optimism, sending CSL shares in circles over the past 18 months.

The most recent broker note on CSL came from Macquarie yesterday. The broker cut its 12-month price target for CSL shares by 1.3% to $308.00. Based on the current CSL share price, this implies an upside of around 5% to investors.

CSL share price snapshot

Over the course of the past 12 months, CSL shares have taken investors on a rollercoaster ride, but are up just 5.08%. The company's shares are currently sitting just above the middle of their 52-week range of $242.00 to $320.42.

On valuation grounds, CSL is the third-largest company on the ASX with a market capitalisation of roughly $133 billion.

Motley Fool contributor Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »

Senior man looking at his laptop and pondering something.
Healthcare Shares

Would I buy ResMed shares after today's results?

The company has reported solid revenue and earnings growth. Here's what I make of its performance and current valuation.

Read more »